Anti-CD73 in cancer immunotherapy: awakening new opportunities.
about
CD73 is expressed by inflammatory Th17 cells in experimental autoimmune encephalomyelitis but does not limit differentiation or pathogenesis.Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions.Pathological overproduction: the bad side of adenosine.The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.CD73s protection of epithelial integrity: Thinking beyond the barrier.Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review.Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.PlanHab Study: Consequences of combined normobaric hypoxia and bed rest on adenosine kinetics.Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.The Hypoxia-Adenosine Link during Intestinal Inflammation.Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages.Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?Exomechip Analyses Identify Genes Affecting Mortality after HLA-Matched Unrelated Donor Blood and Marrow Transplantation.CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells.A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.Unveiling the Role of Ecto-5'-Nucleotidase/CD73 in Astrocyte Migration by Using Pharmacological Tools.Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.CD73 expression and clinical significance in human metastatic melanoma.
P2860
Q36306232-01F96B8E-B774-4D00-837C-551E433C229DQ36343925-9F002CE7-9B7A-4C8E-B12C-8182C5A555A4Q37367538-F3EA1271-DA68-4D13-875E-E5923BB38039Q39157893-ABBB8F52-BB82-4FAE-91A0-B701C29FF609Q39161005-D76E54CA-A7EB-48BF-BDFE-FACF0BC16CD3Q39189908-835FE2B9-4609-4C2C-B8A4-1AD53D39BD63Q40783577-04D7A5BD-9EB8-4697-97A6-BCF503E4B2C2Q41342104-A27CC6A9-CFDB-41FF-BD4B-3BCF44233279Q42387961-A23FCBE2-7330-40CD-93D7-5338F44D2353Q46260887-A19F2BEC-0DEE-49FF-8898-FA4844F6ECFAQ47221234-2232A87D-9598-4102-B576-8C714B030DFCQ48043299-22168881-309E-48E2-8154-C984DC965142Q48150041-8FAF2637-31A3-40D1-A8DE-327649D2B52CQ48187016-B0478EBD-5966-4845-B759-C87199D88089Q48191363-5A933639-23FC-486D-920D-1E7270C9FF08Q49401353-37B1BD29-7AE0-40F7-94F8-1A0D95AE895AQ50096315-B7775D20-0DD2-4FC4-B5FA-989E91EE64F5Q52323624-35CE5478-6A26-4249-8F0F-3C66D9A916C1Q52611870-A2C50634-98F4-42AA-AA80-0E62F71610FEQ52649982-1C2D6124-2492-4BAC-9C71-4170E56BDFF6Q52716939-92F08463-E2D8-431D-9622-7E943487A8C5Q54940978-76587775-7E6B-4F64-A6F1-947BC53EB7CFQ54986388-A78E8713-9410-4661-B447-0B85EB9765E6Q55001315-94CC4AFA-2FDB-4167-A034-F43A46374C54Q55251496-3343C8F4-133C-4996-A455-8B5EDFD776E6Q55282181-6C148115-2875-4EE7-AF81-E2A200AC167C
P2860
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
@ast
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
@en
type
label
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
@ast
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
@en
prefLabel
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
@ast
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
@en
P2860
P50
P1433
P1476
Anti-CD73 in cancer immunotherapy: awakening new opportunities
@en
P2093
György Haskó
Luca Antonioli
P2860
P304
P356
10.1016/J.TRECAN.2016.01.003
P577
2016-02-01T00:00:00Z